Ann: Quarterly Activity Report and Appendix 4C, page-23

Not that it matters, but we had 7 patients in our EMD AML trial.

RAC's drug has been used in more patients than any other ASX listed biotech that is advancing a new drug. It doesn't matter if another company did the trials - if this mattered then no drug would ever get bought by large pharma. Your "expert in biotechs" really hasn't considered that a listed biotech might actually be able to advance a drug with a long and successful clinical history.

RC220 is only at Phase 1 because of regulatory reasons, on clinical risk it is at post approval having already made it all the way to approval in France. The risk around RC220 is not if it will work as an anticancer drug, but if it will work in the commercially most valuable indication (CPACS). At least we will soon find out the answer to this question.